RSI heating up and price attempting to break resistance of the bull flag. Buy and hold
Bio-Path Holdings Inc (NASDAQ:BPTH) I've covered this low floater in the past, and it appears the stock is getting attention again. I've always felt this stock has potential to rally. From a technical standpoint, it needs to break through $6.20 to really get going. A break of that figure brings $7.80 into focus. Keep a close eye on this one the next few days.
I remember seeing this move live in real-time when it happened. It was amazing! Thought of doing a study case of this pattern. The chart is self-explanatory. First, you wait for the first part of the pattern to happen ----> Huge gains + Huge Volume Second, you watch it does the first pullback, and keep an eye on the HIGH. Third, when the stock is making...
Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology Provides Expanded Protection to Seminal Patents Related to DNAbilize The new patent builds on earlier patents granted that protect the platform technology for DNAbilize®, the Company’s novel RNAi nanoparticle drugs. finance.yahoo.com
Hi. Look at this beauty. If you want new shares, like wildly and follow wildly. It is my personal opinion. It isn't investment advice.
Is it time for this beast to reawaken? May 29th we will find out!
Daily looks like bearflag, expect strong move soon to 5.3ish where i will be adding.
BPTH, the ticker to the company Bio Path Holdings is currently trending down. This ticker has been a poor performer for the entire year with small time periods where day traders may make an easy 20-60 percent. Bio Path may seem like a decent day trading target where it follows the downward trending line and tends to bounce up a few days after coming into contact...
BPTH = LONG FLAG ALLERT AS CATALIST EARNING ..PAY ATTENTION from 9$ TP1 18$ TP2 28$ TP 3 35 $ STAY TUNED 95 % RETURN
ANALYSTS UPGRADE WITH $28 TAGRGET H.C. Wainwright analyst Yi Chen started Bio-Path Holdings with a Buy rating and $28 price target. The company possesses an "intriguing" technology platform, DNAbilize, consisting of a novel and proprietary way to achieve sustainable systemic delivery of antisense oligonucleotides, Chen tells investors in a research note. Further,...
Stock picking has no certainties and often the greatest signals are from whispers among the investment community. Bi-Path Holdings has had quite a lot of good news recently that has brought it to the attention of many investors. Despite this we think that the price is gearing up for a significant move upwards, so we have alerts set on price and RSI spikes. This is...
Bio-Path released updated Phase 2 data for its lead candidate prexigebersen, codenamed BP1001, for treating acute myeloid leukemia, or AML, and also divulged a plan of action for taking the compound through clinical development toward registration. Updated data from the Stage 1 of the Phase 2 study that evaluated the efficacy and safety of prexigebersen in...
What the fuck do they have? Cure for AML? other L, other Cancer? i dont' know but it's too cheap here!!